Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings was paid $3.27M by Medicaid between Jan 2018 and Dec 2024, across 26 billing codes. Its largest line is 88175, Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer — 28% of everything it billed.
SYRACUSE, NY 13202
Next to other Clinical Medical Laboratory providers in New York
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 14,909 | $302K | |
| 2019 | 16,755 | $319K | |
| 2020 | 19,912 | $430K | |
| 2021 | 24,124 | $597K | |
| 2022 | 24,806 | $635K | |
| 2023 | 26,853 | $576K | |
| 2024incomplete | 18,989 | $409K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 28% | 46,657 | 46,529 | $916K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 20% | 30,890 | 30,779 | $658K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 15% | 11,964 | 11,581 | $497K |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 9.6% | 3,293 | 3,287 | $312K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 7.0% | 13,191 | 13,148 | $229K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 7.0% | 13,109 | 13,067 | $228K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 2.7% | 4,879 | 4,860 | $87K |
| 88141 | 2.6% | 10,715 | 10,684 | $84K | |
| 88307 | 2.1% | 1,074 | 942 | $67K | |
| 88142 | 1.8% | 3,794 | 3,786 | $58K | |
| 87625 | 1.6% | 2,970 | 2,946 | $52K | |
| 88342 | 1.0% | 1,156 | 1,125 | $34K |
14 more codes
| 88341 | <1% | 402 | $18K | |
| 88304 | <1% | 838 | $14K | |
| 88300 | <1% | 738 | $5K | |
| 81422 | <1% | 171 | $3K | |
| 88112 | <1% | 66 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 51 | $2K |
| 88302 | <1% | 127 | $1K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 171 | $564.30 |
| 88360 | <1% | 12 | $412.99 | |
| 87660 | <1% | 29 | $288.10 | |
| 88312 | <1% | 13 | $190.49 | |
| 87510 | <1% | 13 | $139.78 | |
| 87480 | <1% | 13 | $139.78 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 12 | $126.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.